These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 35956997)

  • 21. 2-Phenylquinazolin-4(3H)-one scaffold as newly designed, synthesized VEGFR-2 allosteric inhibitors with potent cytotoxicity through apoptosis.
    Elrayess R; Elgawish MS; Nafie MS; Ghareb N; Yassen ASA
    Arch Pharm (Weinheim); 2023 Jun; 356(6):e2200654. PubMed ID: 37002183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
    Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
    Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
    Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
    Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis and in┬ávitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
    Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
    Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
    Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
    El-Adl K; Abdel-Rahman AA; Omar AM; Alswah M; Saleh NM
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100237. PubMed ID: 34862655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, antitumor, and VEGFR-2 inhibition activities of novel 4-anilino-2-vinyl-quinazolines: Molecular modeling studies.
    Hamdi A; El-Shafey HW; Othman DIA; El-Azab AS; AlSaif NA; Abdel-Aziz AA
    Bioorg Chem; 2022 May; 122():105710. PubMed ID: 35278776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates
    Eissa IH; El-Haggar R; Dahab MA; Ahmed MF; Mahdy HA; Alsantali RI; Elwan A; Masurier N; Fatahala SS
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1587-1599. PubMed ID: 35637622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers:
    Yousef RG; Elwan A; Gobaara IMM; Mehany ABM; Eldehna WM; El-Metwally SA; A Alsfouk B; Elkaeed EB; Metwaly AM; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2206-2222. PubMed ID: 35980113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
    Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
    Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
    Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
    Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
    Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway.
    Seif SE; Mahmoud Z; Wardakhan WW; Abdou AM; Hassan RA
    Drug Dev Res; 2023 Aug; 84(5):839-860. PubMed ID: 37016480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.